secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001628280-23-006697
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q4 revenues down 4% YoY to $10.7M; guides FY2023 rev $37-41M; AQST-109 pivotal study on track for Q3
--------------------------------------------------------------------------------

- Q4 2022 total revenues $10.7M vs $11.1M YoY; net loss $12.4M ($0.23/sh) vs $28.9M ($0.72/sh) in Q4 2021.
- Full year 2022 total revenues $47.7M, down 6% YoY; net loss $54.4M ($1.12/sh) vs $70.5M ($1.85/sh).
- FY2023 guidance: total revenue $37-41M; non-GAAP adjusted EBITDA loss $31-36M.
- AQST-109 pivotal study protocol to be submitted to FDA in Q2 2023; study start expected Q3 2023.
- Patent litigation settled with BDSI for $8.5M payment to Aquestive; Indivior agreement extended to 2026 with $11.5M one-time payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/0001628280-23-006697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023006697/aqst-20230307.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-006697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer